Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Glaucoma Matrix > Single Agent Adjuncts > Flashcards

Single Agent Adjuncts Flashcards

1
Q

ALPHAGAN P .1%
Indication
Contraindication
Admin
AE
DDI
max IOP reduction

A

-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or tartrate or any components
-TID, 8 hours apart
-allergic conjunctivitis, conjunctival hyperemia, eye pruritus
-antihypertensives, cardiac glycosides, CNS depressants, TCAs, MAO inhibitors
-2-6 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

BRIMONIDINE .15%
Indication
Contraindication
Admin
AE
DDI
max IOP reduction

A

-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or any components
-TID, about 8 hours apart
-allergic conjunctivitis, conjunctival hyperemia, eye pruritus
-anti hypertensives, cardiac glycosides, CNS depressant, TCAs, MAO inhibitors
-2-6 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

BRIMONIDINE .2%
Indication
Contra
Admin
AE
DDI
max IOP reduction

A

-reduction of IOP in OAG or OHT
-neonates and infants, hypersensitivity to brimonidine or any components
-TID, about 8 hours apart
-oral dryness
-anti hypertensives, cardiac glycosides, CNS depressant, TCAs, MAO inhibitors
-4-6 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

AZOPT
Indication
Contra
Admin
AE
DDI
max IOP reduction

A

-reduce IOP
-hypersensitivity to brinzolamide or any components
-TID
-blurred vision, dysgeusia
-oral CAIs, high dose salicylate
-4-5 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

TRUSOPT
indication
contra
admin
AE
DDI
max IOP

A

-reduction of elevated IOP
-hypersensitivity to dorzolamide hydrochloride or any components
-TID
-ocular irritation
-oral CAIs, high dose salicylate
-3-5 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

TIMOLOL
indication
contra
admin
AE
DDI
max IOP

A

-treatment of elevated IOP
-bronchial asthma, severe COPD, cardiac cardiac problems, hypersensitivity to timolol maleate or any of its components
-QD
-blurred vision or instillation
-oral b-blockers, digitalis, alcium antagonists, catecholamine-depleting drugs, quindidine, clonidine, injectable epinephrine
-6 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ISOPTO CARPINE
indication
contra
admin
AE
DDI
max IOP

A

-reduction of elevated IOP, management of AACG, prevention of post op IOP increase from laser surgery, induction of miosis
-none
-up to QID
-accommodative change, blurred vision, ocular irritation/pain, visual impairment, headache/brow ache
-none
-3-7 mm Hg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ALPHAGAN P .1%
active ingredient

A

brimonidine tartrate .1% or .15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

ALPHAGAN P .1%
class

A

a-agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ALPHAGAN P .1%
proposed MOA

A

reduce aqueous production and increase uveoscleral outflow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ALPHAGAN P .1%
bottle size availability

A

5 mL in a 10 mL bottle
10 mL in a 10 mL bottle
15 mL in a 15 mL bottle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BRIMONIDINE .15%
active ingredient

A

brimonidine tartrate .15%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

BRIMONIDINE .15%
class

A

a-agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

BRIMONIDINE .15%
proposed MOA

A

reduce aqueous production and increase uveoscleral outflow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

BRIMONIDINE .15%
bottle size availability

A

5 mL in a 5 mL bottle
10 mL in 11 mL bottle
15 mL in a 15 mL bottle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BRIMONIDINE .2%
active ingredient

A

brimonidine tartrate .2%

17
Q

BRIMONIDINE .15%
class

A

a-agonist

18
Q

BRIMONIDINE .15%
proposed MOA

A

reduced aqueous production and increase uveoscleral outflow

19
Q

BRIMONIDINE .15%
bottle size

A

5 mL
10 mL
15 mL

20
Q

AZOPT
active ingredient

A

brinzolamide 1%

21
Q

AZOPT
class

A

CAI

22
Q

AZOPT
proposed MOA

A

decrease aqueous production

23
Q

AZOPT
bottle size

A

10 mL
15 mL

24
Q

TRUSOPT
active ingredient

A

dorzolamide hydrochloride

25
Q

AZOPT
class

A

CAI

26
Q

AZOPT
proposed MOA

A

decrease aqueous production

27
Q

AZOPT
bottle size

A

10 mL in 18 mL bottle

28
Q

TIMOLO
active ingredient

A

timolo maleate .25% or .5%

29
Q

TIMOLO
class

A

b-blocker

29
Q

TIMOLO
proposed MOA

A

reduce aqueous formation, possibly also increase aqueous outflow

29
Q

ISOPTO CARPINE
active ingredient

A

pilocarpine 1%, 2%, 4%

30
Q

TIMOLO
bottle size

A

2.5 mL
5 mL

31
Q

TIMOLO
class

A

cholinergic agonist

32
Q

TIMOLO
proposed MOA

A

increase aqueous outflow

33
Q
A

Glaucoma Matrix (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions